- Home
- GITS vs PULM Comparison
GITS vs PULM Comparison
Compare GITS & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GITS | PULM |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | South Korea | United States |
| Employees | 5 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 5.2M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | GITS | PULM |
|---|---|---|
| Price | $1.54 | $1.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.4K | ★ 29.7K |
| Earning Date | 11-20-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $67.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5069.93 |
| 52 Week Low | $0.66 | $1.06 |
| 52 Week High | $7.09 | $4.98 |
Technical Indicators
Market Signals| Indicator | GITS | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 47.35 |
| Support Level | $1.42 | $1.23 |
| Resistance Level | $2.87 | $1.46 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 40.47 | 62.59 |
Price Performance
Historical ComparisonAbout GITS Global Interactive Technologies Inc.
Global Interactive Technologies Inc is operating and developing Faning, a digital fan engagement platform focused on Korean entertainment and culture, including K-pop. Faning is designed to support online fan communities, user interaction, multilingual communication, and digital engagement experiences across mobile and web-based services. The platform evolved from the legacy Fantoo platform ecosystem. The Company's primary operational focus was the continued development, maintenance, and support of the Faning platform. The Company operates its business through its core Faning platform and strategy.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).